Core Viewpoint - Benda Pharmaceutical's stock has experienced a decline in recent trading sessions, with a notable drop in both share price and market capitalization, indicating potential challenges in the company's performance and investor sentiment [1][2]. Company Performance - As of September 30, Benda Pharmaceutical reported a revenue of 2.717 billion yuan, reflecting a year-on-year growth of 15.90%. However, the net profit attributable to shareholders decreased by 23.86% to 317 million yuan [2]. - The company's stock price has fallen by 5.40% year-to-date, with a 5.71% decline over the past five trading days, a 12.75% drop over the last 20 days, and a significant 27.60% decrease over the past 60 days [1]. Shareholder Information - The number of shareholders decreased by 7.99% to 29,500, while the average number of circulating shares per person increased by 8.68% to 14,198 shares [2]. - Benda Pharmaceutical has distributed a total of 669 million yuan in dividends since its A-share listing, with 184 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, notable institutional shareholders include Xingquan Commercial Model Mixed Fund (LOF) A, which is the fifth-largest shareholder with 5.827 million shares, and E-Fund's Growth Enterprise Board ETF, which has reduced its holdings by 912,300 shares [3].

Core Viewpoint - The stock of Jibeier has experienced a decline recently despite a year-to-date increase, indicating potential volatility in its market performance [2]. Group 1: Stock Performance - As of November 19, Jibeier's stock price decreased by 2.00%, trading at 29.33 CNY per share with a total market capitalization of 5.849 billion CNY [1]. - Year-to-date, Jibeier's stock has risen by 34.05%, but it has seen a decline of 5.99% over the last five trading days, 8.00% over the last 20 days, and 21.28% over the last 60 days [2]. Group 2: Company Overview - Jibeier Pharmaceutical Co., Ltd. was established on November 13, 2001, and went public on May 18, 2020. The company specializes in the research, production, and sales of pharmaceuticals [2]. - The main revenue sources for Jibeier include Likujun tablets (72.72%), Nigulol tablets (14.20%), Yipingfeng capsules (4.88%), and others [2]. Group 3: Financial Performance - For the period from January to September 2025, Jibeier reported a revenue of 704 million CNY, reflecting a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million CNY, which is a 12.80% increase year-on-year [2]. - Since its A-share listing, Jibeier has distributed a total of 476 million CNY in dividends, with 252 million CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, Jibeier had 7,742 shareholders, an increase of 28.97% from the previous period, with an average of 25,759 circulating shares per shareholder, a decrease of 22.46% [2]. - Notable new institutional shareholders include Caitong Advantage Industry Rotation Mixed Fund and GF Healthcare Stock A, holding 1.2392 million shares and 959,000 shares respectively [3].

资金流向方面，主力资金净流出5.42万元，大单买入441.13万元，占比15.25%，卖出446.55万元，占比 15.44%。 11月19日，诺诚健华盘中下跌2.20%，截至10:04，报23.95元/股，成交2893.07万元，换手率0.45%，总 市值422.63亿元。 诺诚健华今年以来股价涨95.03%，近5个交易日跌4.77%，近20日涨3.63%，近60日跌24.71%。 资料显示，诺诚健华医药有限公司位于北京市昌平区中关村生命科学园生命园路8号院8号楼，成立日期 2015年11月3日，上市日期2022年9月21日，公司主营业务涉及诺诚健华医药有限公司是一家主要从事生 物医药的研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求 的领域，其产品管线包括ICP-022、ICP-B04、ICP-490、ICP-192、ICP-723、ICP-022等。该公司主要在 中国和美国开展业务。主营业务收入构成为：药品销售87.67%，技术授权12.04%，检测服务0.15%，研 发服务0.15%。 诺诚健华所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：生物医药、 ...

资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 舒泰神所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：生物医药、抗癌治癌、创 新药、仿制药、AI医药等。 11月19日，舒泰神盘中下跌2.02%，截至09:54，报34.02元/股，成交2.87亿元，换手率1.84%，总市值 162.54亿元。 资金流向方面，主力资金净流出2941.53万元，特大单买入1076.11万元，占比3.75%，卖出2220.02万 元，占比7.74%；大单买入5187.11万元，占比18.10%，卖出6984.73万元，占比24.37%。 舒泰神今年以来股价涨359.11%，近5个交易日跌8.62%，近20日跌11.45%，近60日跌41.65%。 今年以来舒泰神已经8次登上龙虎榜，最近一次登上龙虎榜为10月31日，当日龙虎榜净买入3. ...

11月19日，京新药业盘中下跌2.01%，截至09:38，报20.48元/股，成交1.27亿元，换手率0.85%，总市值 176.34亿元。 京新药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：阿尔茨海默、抗癌治 癌、眼科概念、生物医药、创新药等。 截至9月30日，京新药业股东户数2.23万，较上期减少13.08%；人均流通股32438股，较上期增加 15.05%。2025年1月-9月，京新药业实现营业收入30.48亿元，同比减少5.00%；归母净利润5.76亿元，同 比增长0.10%。 分红方面，京新药业A股上市后累计派现21.10亿元。近三年，累计派现8.01亿元。 机构持仓方面，截止2025年9月30日，京新药业十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股745.88万股，相比上期减少219.04万股。 责任编辑：小浪快报 资金流向方面，主力资金净流出165.99万元，特大单买入628.85万元，占比4.95%，卖出725.96万元，占 比5.71%；大单买入2673.29万元，占比21.04%，卖出2742.17万元，占比21.58%。 京新药业今年以来股价涨64 ...

Core Viewpoint - Zhaoli Pharmaceutical's stock has experienced a decline of 2.05% on November 17, with a current price of 17.23 CNY per share and a market capitalization of 12.085 billion CNY, despite a year-to-date increase of 16.67% [1] Financial Performance - For the period from January to September 2025, Zhaoli Pharmaceutical reported a revenue of 2.28 billion CNY, reflecting a year-on-year growth of 11.48%, and a net profit attributable to shareholders of 510 million CNY, which is a 21.00% increase compared to the previous year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.442 billion CNY, with 942 million CNY distributed over the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 41,400, up by 7.31%, while the average number of circulating shares per person decreased by 6.82% to 14,562 shares [2] - Among the top ten circulating shareholders, the "Innovative Medicine" fund holds 6.8549 million shares, an increase of 280,700 shares, while the "Southern CSI 1000 ETF" holds 6.4172 million shares, a decrease of 58,800 shares [3] Stock Performance - Zhaoli Pharmaceutical's stock has seen a decline of 2.43% over the last five trading days, 6.92% over the last twenty days, and 13.29% over the last sixty days [1] - The stock's trading volume on November 17 was 58.7402 million CNY, with a turnover rate of 0.56% [1] Business Overview - Zhaoli Pharmaceutical, established on January 28, 2000, and listed on February 22, 2011, specializes in the research, production, and sales of medicinal fungi, traditional Chinese medicine pieces, and formula granules [1] - The company's main revenue sources include the Wuling series (56.07%), traditional Chinese medicine pieces (21.85%), and other products [1] Industry Classification - Zhaoli Pharmaceutical is classified under the pharmaceutical and biotechnology sector, specifically in traditional Chinese medicine [1] - The company is associated with various concept sectors, including value growth, cell therapy, precision medicine, cancer treatment, and innovative drugs [1]

Core Viewpoint - Nanwei Medical's stock price has experienced fluctuations, with a recent decline of 2.08% and a year-to-date increase of 24.22% [1][2]. Group 1: Stock Performance - As of November 17, Nanwei Medical's stock price is 82.11 CNY per share, with a market capitalization of 15.424 billion CNY [1]. - The stock has seen a decline of 1.00% over the last five trading days, 5.62% over the last 20 days, and 15.71% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Nanwei Medical reported a revenue of 2.381 billion CNY, representing a year-on-year growth of 18.29%, and a net profit attributable to shareholders of 509 million CNY, up 12.90% year-on-year [2]. - The company has distributed a total of 978 million CNY in dividends since its A-share listing, with 664 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Nanwei Medical is 12,500, an increase of 1.38% from the previous period [2]. - The average number of circulating shares per shareholder is 15,009, which has decreased by 1.36% from the previous period [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest with 3.6594 million shares, while Huabao CSI Medical ETF has reduced its holdings by 459,000 shares [3].

Core Viewpoint - Baiotai's stock price has shown a year-to-date increase of 34.93%, but recent trading indicates a decline in the short term, with a notable drop of 21.45% over the past 60 days [2] Company Overview - Baiotai Biopharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on July 28, 2003, with its listing date on February 21, 2020 [2] - The company focuses on the research and production of innovative drugs and biosimilars, with its main business revenue composition being: 91.90% from drug sales, 6.55% from licensing, 0.90% from contract manufacturing, and 0.65% from technical services [2] Financial Performance - For the period from January to September 2025, Baiotai achieved an operating income of 684 million yuan, representing a year-on-year growth of 17.57%, while the net profit attributable to shareholders was -224 million yuan, reflecting a year-on-year increase of 38.72% [2] Stock Market Activity - As of November 17, Baiotai's stock price was 26.15 yuan per share, with a trading volume of 13.01 million yuan and a turnover rate of 0.12%, resulting in a total market capitalization of 10.828 billion yuan [1] - The net outflow of main funds was 120,900 yuan, with large single purchases amounting to 588,900 yuan (4.53% of total) and sales of 709,800 yuan (5.45% of total) [1] Shareholder Information - As of September 30, 2025, the number of Baiotai's shareholders was 9,397, a decrease of 0.89% from the previous period, with an average of 44,065 circulating shares per person, an increase of 0.89% [2] - Hong Kong Central Clearing Limited is the tenth largest circulating shareholder, holding 6.0247 million shares as a new shareholder [2]

Core Viewpoint - Rongchang Biopharmaceuticals has experienced significant stock price fluctuations and changes in shareholder composition, reflecting its ongoing developments in the biopharmaceutical sector and market dynamics [1][3][4]. Group 1: Stock Performance - As of November 17, Rongchang Biopharmaceuticals' stock price decreased by 2.01%, trading at 88.27 CNY per share, with a market capitalization of 49.759 billion CNY [1]. - The stock has increased by 193.16% year-to-date, with a slight increase of 0.02% over the last five trading days, a decrease of 6.59% over the last 20 days, and an increase of 14.65% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent instance on June 26, where it recorded a net buy of -137 million CNY [1]. Group 2: Company Overview - Rongchang Biopharmaceuticals, established on July 4, 2008, and listed on March 31, 2022, is based in Yantai, Shandong, China, focusing on innovative biopharmaceuticals, particularly in antibody-drug conjugates (ADC) and therapeutic antibodies [2]. - The company aims to develop first-in-class and best-in-class biopharmaceuticals to address unmet clinical needs in autoimmune diseases, oncology, and ophthalmology [2]. - The revenue composition shows that 99.46% comes from product sales, with minimal contributions from material sales and leasing services [2]. Group 3: Financial Performance - For the period from January to September 2025, Rongchang Biopharmaceuticals reported a revenue of 1.72 billion CNY, representing a year-on-year growth of 42.27%, while the net profit attributable to shareholders was -551 million CNY, an increase of 48.60% year-on-year [3]. Group 4: Shareholder Composition - As of September 30, 2025, the number of shareholders increased by 18.33% to 15,300, with an average of 10,639 circulating shares per shareholder, a decrease of 15.54% [3]. - The second-largest shareholder is Hong Kong Central Clearing Limited, holding 8.8418 million shares, a decrease of 510,800 shares from the previous period [4]. - Other notable shareholders include Wanjiayou Selected (increased by 1.0755 million shares) and new entrant Guangfa Healthcare Stock A [4].

11月14日，奥赛康盘中上涨2.01%，截至10:46，报19.78元/股，成交2.00亿元，换手率1.10%，总市值 183.59亿元。 资金流向方面，主力资金净流入424.22万元，特大单买入114.65万元，占比0.57%，卖出0.00元，占比 0.00%；大单买入3167.53万元，占比15.86%，卖出2857.96万元，占比14.31%。 奥赛康今年以来股价涨57.11%，近5个交易日涨6.75%，近20日涨1.59%，近60日跌25.44%。 今年以来奥赛康已经2次登上龙虎榜，最近一次登上龙虎榜为7月16日。 资料显示，北京奥赛康药业股份有限公司位于江苏省南京市江宁科学园科建路699号，成立日期1996年 12月24日，上市日期2015年5月15日，公司主营业务涉及消化类、抗肿瘤类及其他药品的研发、生产和 销售。主营业务收入构成为：抗肿瘤类38.28%，抗感染类24.74%，慢性病类21.65%，消化类12.33%， 其他(补充)2.34%，其他类0.66%。 奥赛康所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗癌治癌、创新药、生物 医药、幽门螺杆概念、中盘等。 截至10月2 ...